Trials / Completed
CompletedNCT06086340
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Comparative Assessment of Overall Survival in Medicare Patients With HR+/HER2- Metastatic Breast Cancer Treated With Palbociclib in Combination With Aromatase Inhibitor (AI vs. AI Alone)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 779 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib | Palbociclib with an aromatase inhibitor therapy |
| DRUG | Aromatase Inhibitor | Aromatase Inhibitor Therapy |
Timeline
- Start date
- 2023-09-29
- Primary completion
- 2024-01-24
- Completion
- 2024-01-24
- First posted
- 2023-10-17
- Last updated
- 2025-11-18
- Results posted
- 2025-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06086340. Inclusion in this directory is not an endorsement.